Aluminum Hydroxide
| Evidence Level: L3 | Predicted Indications: 4 |
Table of Contents
Aluminum Hydroxide: From Antacid Use to Active Peptic Ulcer Disease
One-Sentence Summary
Aluminum hydroxide is a long-marketed antacid that neutralizes stomach acid. The TxGNN model predicts it may be effective for active peptic ulcer disease. This is close to established use rather than true repurposing. Support is 0 registered clinical trials and 18 publications, mostly from the 1970s to 1990s.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the license records (long-marketed antacid) |
| Predicted New Indication | Active peptic ulcer disease |
| TxGNN Prediction Score | 99.64% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the DrugBank record. The literature describes aluminum hydroxide as neutralizing gastric hydrochloric acid, raising intragastric pH and reducing pepsin activity. Several studies also report mucosal cytoprotection, possibly through endogenous prostaglandins (PMID 1769429, 22950493).
Peptic ulcers are driven by acid and pepsin injury to the mucosa. Acid neutralization and mucosal protection therefore match the disease pathophysiology directly. Older reviews report that intensive antacid therapy heals duodenal ulcers about as well as cimetidine, but with more side effects. Its effect on gastric ulcer healing is smaller and less certain.
The evidence predates proton pump inhibitors (PPIs) and H. pylori eradication therapy. The realistic role today is adjunct or symptomatic therapy, not first-line ulcer treatment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7034155 | 1981 | RCT | Scand J Gastroenterol | 12-week double-blind trial in 72 patients with duodenal or prepyloric ulcers. Antacid/anticholinergic was compared with cimetidine and placebo. Cimetidine healed 67% at 3 weeks (p<0.005 vs placebo). |
| 1769429 | 1991 | Mechanistic/Clinical pharmacology | Digestion | Aluminum-containing antacids, including Al(OH)3, protected against experimentally induced gastric mucosal lesions. The study examined the role of intragastric pH. |
| 22950493 | 2013 | Review | Curr Pharm Des | Reviews the mucosal protective and ulcer-healing actions of antacids at the cellular and molecular level. |
| 37146 | 1979 | Review | Fortschr Med | Antacid use in peptic ulcer is based on neutralizing gastric acid and inhibiting pepsin. Adequate dosing after meals is needed. |
| 6086186 | 1984 | Review | Clin Gastroenterol | Reviews antacids and anticholinergics in duodenal ulcer treatment. |
| 6927335 | 1982 | Review | Pharmacotherapy | Reviews sucralfate, a polyaluminum hydroxide complex with a sulfated disaccharide. It is non-systemic and protects the ulcer crater. It is not an antacid, but it is a related aluminum-based agent. |
| 2401189 | 1990 | Cohort | Drugs Exp Clin Res | Retrospective study of 267 children with peptic symptoms. It examined treatment of the acute phase and of relapses. |
| 3018068 | 1986 | Clinical pharmacology | J Clin Gastroenterol | Compared postprandial gastric acid buffering of sodium bicarbonate and aluminum-magnesium hydroxide in duodenal ulcer patients. |
| 2390927 | 1990 | Preclinical | Dig Dis Sci | Al(OH)3 enhanced healing of chronic gastroduodenal ulcers in rats. Prostaglandins and epidermal growth factor were examined as mediators. |
| 9334882 | 1997 | Preclinical | Jpn J Pharmacol | Al(OH)3 prevented acid- and pepsin-induced damage in rat gastric epithelial cells. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M001 | Aluminum Hydroxide (Rugby Laboratories) | Liquid | Not stated in the record |
| M | Aluminum Hydroxide (Atlantic Biologicals Corp.) | Liquid | Not stated in the record |
| M016 | ProCure DryDrox (Twin Med LLC) | Ointment | Not stated in the record |
Safety Considerations
Please refer to the package insert for safety information. No warning, contraindication or interaction data are available in the record, and the drug-interaction query returned no results.
Guardrails from the evidence review:
- Renal impairment: monitor for aluminum accumulation.
- Hypophosphatemia: aluminum hydroxide can cause phosphate depletion, and long-term use may lead to bone demineralization (PMID 6293043).
- Drug-binding interactions: check concomitant medicines that may bind to or be affected by antacids.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism directly matches ulcer pathophysiology, and randomized and pharmacology studies support the direction. Nearly all evidence is 1970s–1990s, has no registered trials, and predates PPIs and H. pylori eradication. It is therefore capped at L3.
To proceed, the following is needed:
- Verify the design and phase of the 1981 RCT (PMID 7034155) and the 1977 controlled trials of aluminum hydroxide gels (PMID 324863). Confirming adequate randomized trials could raise the level to L2 or L1.
- Package insert warnings and contraindications, which are currently missing and block safety screening.
- Detailed mechanism-of-action data from DrugBank.
- Positioning limited to adjunct or symptomatic use, not a replacement for PPIs or H. pylori eradication.
Other predicted indications are weaker. Gastroduodenitis and gastrojejunal ulcer rest on indirect evidence only. Peptic ulcer perforation is not a plausible antacid indication.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.